var data={"title":"Latanoprost: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Latanoprost: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6439?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=latanoprost-drug-information\" class=\"drug drug_general\">see &quot;Latanoprost: Drug information&quot;</a> and <a href=\"topic.htm?path=latanoprost-patient-drug-information\" class=\"drug drug_patient\">see &quot;Latanoprost: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187060\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xalatan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187061\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Latanoprost;</li>\n      <li>Apo-Latanoprost;</li>\n      <li>GD-Latanoprost;</li>\n      <li>Med-Latanoprost;</li>\n      <li>Monoprost;</li>\n      <li>PMS-Latanoprost;</li>\n      <li>Riva-Latanoprost;</li>\n      <li>Sandoz-Latanoprost;</li>\n      <li>Xalatan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021322\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Ophthalmic Agent, Antiglaucoma</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Prostaglandin, Ophthalmic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021347\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=latanoprost-drug-information\" class=\"drug drug_general\">see &quot;Latanoprost: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Reduction of intraocular pressure:</b> Limited data available: Infants, Children, and Adolescents: 1 drop to affected eye(s) once daily in the evening (Maeda-Chubachi 2013; Quaranta 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Elevated intraocular pressure:</b> Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage (may decrease the IOP-lowering effect)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187064\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=latanoprost-drug-information\" class=\"drug drug_general\">see &quot;Latanoprost: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Elevated intraocular pressure:</b> Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage (may decrease the IOP-lowering effect)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990698\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There is no dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988025\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There is no dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187043\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xalatan: 0.005% (2.5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.005% (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187029\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021350\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmic: Wash hands before use. Unscrew the cap by turning in the direction of the arrows on top of the cap. Pull lower eyelid down slightly to form a pocket for the eye drop and tilt head back; administer 1 drop. Apply gentle pressure to lacrimal sac immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration to decrease systemic absorption of ophthalmic drops (Urtti 1993; Zimmerman 1982). Avoid contact of bottle tip with skin or eye; remove contact lenses prior to administration and wait at least 15 minutes after instillation before reinserting soft contact lenses. If more than one topical ophthalmic drug is being used, separate administration by at least 5 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187058\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact bottles under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Once opened, the container may be stored at room temperature up to 25&deg;C (77&deg;F) for 6 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021323\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187095\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Latanoprost may be confused with Lantus</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xalatan may be confused with Lantus, Travatan, Xalacom, Zarontin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187094\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, chest pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Foreign body sensation of eye</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic skin reaction, erythema of eyelid, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, burning sensation of eyes, conjunctival hyperemia, crusting of eyelid, dry eye syndrome, epithelial keratopathy (punctate), eyelid edema, eyelid pain, eye pain, eye pruritus, iris hyperpigmentation, lacrimation, photophobia, stinging of eyes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Asthma, conjunctivitis (including pseudopemphigoid of the ocular conjunctiva), corneal edema, corneal erosion, dizziness, dyspnea, exacerbation of asthma, eye disease (periorbital and lid changes resulting in deepening of the eyelid sulcus), headache, herpes simplex keratitis, hyperpigmentation of eyelashes, hyperpigmentation of eyelids, increased eyelash length, increased eyelash thickness, increased growth in number of eyelashes, iris cyst, iritis, keratitis, macular edema (including cystoid macular edema), misdirected growth of eyelashes, palpitations, pruritus, toxic epidermal necrolysis, unstable angina pectoris, uveitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187049\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to latanoprost, benzalkonium chloride, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187033\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes; length and/or number of eyelashes may also be increased. Pigmentation of the iris is likely to be permanent although iris color change may not be noticeable for months to years; pigmentation of the periorbital tissue and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences and potential injury to eye are not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular inflammation: Intraocular inflammation and exacerbation of inflammation may occur; use with caution in patients with a history of intraocular inflammation (eg, iritis/uveitis) and generally avoid use in patients with active intraocular inflammation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Herpetic keratitis: Use with caution in patients with a history of herpes simplex keratitis; reactivation may occur. Avoid use in patients with active herpes simplex keratitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Safety and efficacy have not been determined for use in patients with angle-closure, inflammatory, or neovascular glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Contains benzalkonium chloride which may be absorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299578\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187038\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=117285&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bimatoprost: The concomitant use of Latanoprost and Bimatoprost may result in increased intraocular pressure. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187040\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13376205\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies at maternally toxic doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187032\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Latanoprost is a prostaglandin F<sub>2</sub>-alpha analog believed to reduce intraocular pressure by increasing the outflow of the aqueous humor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187048\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 3 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Maximum: 8 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Through the cornea where the isopropyl ester prodrug is hydrolyzed by esterases to the biologically active acid. Peak concentration is reached in 2 hours after topical administration in the aqueous humor. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.16 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic via fatty acid beta-oxidation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 17 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021361\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Xalatan)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.005% (2.5): $50.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.005% (2.5): $58.22</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187052\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>9 PM eye drops (IN);</li>\n      <li>Glautan (IL);</li>\n      <li>Iprost (BD);</li>\n      <li>Lanoprost (TW);</li>\n      <li>Lanotan (KR, TH, UA);</li>\n      <li>Latacris (IE);</li>\n      <li>Latalux (LV);</li>\n      <li>Latano (ET, QA);</li>\n      <li>Latanox (CO);</li>\n      <li>Latapres (BD, HR);</li>\n      <li>Lataprost (MY, QA);</li>\n      <li>Lataro (KR);</li>\n      <li>Latep (LK);</li>\n      <li>Latipress (PH);</li>\n      <li>Latizodil (LV);</li>\n      <li>Latochek (SG);</li>\n      <li>Latof (PY);</li>\n      <li>Latop (IE);</li>\n      <li>Latoprost (LK);</li>\n      <li>Louten (AR, CL, EC, PY, UY);</li>\n      <li>Monopost (GB, IE);</li>\n      <li>Ocuprost (BD);</li>\n      <li>Prosdrop (TH);</li>\n      <li>Protan (KR);</li>\n      <li>Unilat (HR, RO, UA);</li>\n      <li>Vislat (LK);</li>\n      <li>Vizipres (UA);</li>\n      <li>Xalaprost (BD, MT);</li>\n      <li>Xalatan (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, VE, VN, YE, ZA);</li>\n      <li>Xalavist (PH);</li>\n      <li>Xaprost (TH);</li>\n      <li>Zakol (PE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Maeda-Chubachi T, Chi-Burris K, Simons B, et al. Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost. <i>J Glaucoma</i>. 2013;22(8):614-619.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/latanoprost-pediatric-drug-information/abstract-text/23524858/pubmed\" target=\"_blank\" id=\"23524858\">23524858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quaranta L, Biagioli E, Riva I, et al. The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results. <i>J Glaucoma</i>. 2017;26(11):987-994.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/latanoprost-pediatric-drug-information/abstract-text/28957960/pubmed\" target=\"_blank\" id=\"28957960\">28957960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/latanoprost-pediatric-drug-information/abstract-text/8100087/pubmed\" target=\"_blank\" id=\"8100087\">8100087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xalatan (latanoprost) [prescribing information]. New York, NY: Pfizer; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984;102(4):551-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/latanoprost-pediatric-drug-information/abstract-text/6704011/pubmed\" target=\"_blank\" id=\"6704011\">6704011</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 117285 Version 2.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187060\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187061\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1021322\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1021347\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F187064\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990698\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988025\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187043\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F187029\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1021350\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187058\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1021323\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187095\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187094\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187049\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187033\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299578\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187038\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187040\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13376205\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187032\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F187048\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F1021361\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187052\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/117285|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=latanoprost-drug-information\" class=\"drug drug_general\">Latanoprost: Drug information</a></li><li><a href=\"topic.htm?path=latanoprost-patient-drug-information\" class=\"drug drug_patient\">Latanoprost: Patient drug information</a></li></ul></div></div>","javascript":null}